A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States.

ABSTRACT:

Background

This cross-sectional study aimed to track population-based SARS-CoV-2 antibody seropositivity duration across the United States using observational data from a national clinical laboratory registry of patients tested by nucleic acid amplification (NAAT) and serologic assays. Knowledge of antibody seropositivity and its duration may help dictate post-pandemic planning.

Methods

Using assays to detect antibodies to either nucleocapsid (N) or spike (S) proteins performed on specimens from 39,086 individuals with confirmed positive COVID-19 by reverse transcription-polymerase chain reaction (RT-PCR) from March 2020 to January 2021, we analyzed nationwide seropositivity rates of IgG up to 300 days following patients' initial positive NAAT test. Linear regr

SUBMITTER: Alfego D 

PROVIDER: S-EPMC8143650 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature